AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.
Tidal Investments LLC lowered its position in AptarGroup, Inc. (NYSE: ATR) by 24.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,987 shares of the industrial products company's stock after selling 5,814 shares during the quarter. Tidal Investments LLC's holdings
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in AptarGroup, Inc. (NYSE: ATR) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,200 shares of the industrial products company's stock, valued at approximately $526,000. Other institutional investors have also recently bought and
AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results from the STAR-T trial and are expected to form a core component of additional real-world evidence planned for a new U.S. FDA De Novo submission for DrugSorb-ATR® Recent FDA Pre-Submission meetings provided constructive feedback on potential U.S. regulatory pathways for DrugSorb-ATR for separate applications for ticagrelor and direct oral anticoagulant removal in urgent cardiac surgery PRINCETON, N.J., Sept. 2, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery on the blood thinner, ticagrelor (Brilinta®/Brilique®, AstraZeneca).
Callan Family Office LLC acquired a new stake in AptarGroup, Inc. (NYSE: ATR) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,429 shares of the industrial products company's stock, valued at approximately $1,181,000. A number of other
Deutsche Bank AG bought a new stake in AptarGroup, Inc. (NYSE: ATR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 119,035 shares of the industrial products company's stock, valued at approximately $14,903,000. Deutsche Bank AG owned approximately 0.19% of
Aurora Investment Counsel acquired a new stake in shares of AptarGroup, Inc. (NYSE: ATR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,785 shares of the industrial products company's stock, valued at approximately $1,475,000. Other hedge funds have
